Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8717)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 10, 2016 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zafrakas M, Papasozomenou P, Emmanouilides C. Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials. World J Clin Oncol 2016; 7(4): 331-336 [PMID: 27579253 DOI: 10.5306/wjco.v7.i4.331] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v7/i4/331.htm |
| Number | Citing Articles |
| 1 |
Sharath Mohan Bhat, Palla Ranga Prasad, Manjunath B. Joshi. Epigenetic Regulation of Cancer - Part A. International Review of Cell and Molecular Biology 2023; 380: 63 doi: 10.1016/bs.ircmb.2023.04.002
|
| 2 |
Shang Liu, Ying Liu, Qing Chang, Christian Celia, Xiaoyong Deng, Yijun Xie. pH-Responsive Sorafenib/Iron-Co-Loaded Mesoporous Polydopamine Nanoparticles for Synergistic Ferroptosis and Photothermal Therapy. Biomacromolecules 2024; 25(1): 522 doi: 10.1021/acs.biomac.3c01173
|
| 3 |
Zhuo-Yue Li, Yi-Fan Yin, Yang Guo, Hui Li, Mei-Qi Xu, Man Liu, Jing-Ru Wang, Zhen-Han Feng, Xiao-Chuan Duan, Shuang Zhang, Shuai-Qiang Zhang, Guang-Xue Wang, Ai Liao, Shu-Min Wang, Xuan Zhang. <p>Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid</p>. International Journal of Nanomedicine 2020; : 1809 doi: 10.2147/IJN.S240436
|
| 4 |
Lavanya Ponnusamy, Sathan Raj Natarajan, Karthik Thangaraj, Ravi Manoharan. Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2020; 1874(1): 188379 doi: 10.1016/j.bbcan.2020.188379
|
| 5 |
Shi Huang, Yan Chen, Lingyu Pan, Changyi Fei, Ni Wang, Furui Chu, Daiyin Peng, Xianchun Duan, Yongzhong Wang. Exploration of the Potential Mechanism of Tao Hong Si Wu Decoction for the Treatment of Breast Cancer Based on Network Pharmacology and In Vitro Experimental Verification. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.731522
|
| 6 |
Qi Wang, Nan Cheng, Wei Wang, Yongping Bao. Synergistic Action of Benzyl Isothiocyanate and Sorafenib in a Nanoparticle Delivery System for Enhanced Triple-Negative Breast Cancer Treatment. Cancers 2024; 16(9): 1695 doi: 10.3390/cancers16091695
|
| 7 |
Seraphina Choi, Isabella Dreyfuss, Crystal Seldon Taswell, Jonathan Cyriac, Michael Butkus, Cristiane Takita.
Proton Beam Therapy for Breast Cancer
. Critical Reviews™ in Oncogenesis 2024; 29(3): 67 doi: 10.1615/CritRevOncog.2023050319
|
| 8 |
Zahra Sadat Hashemi, Mahlegha Ghavami, Seyed Hossein Kiaie, Fateme Mohammadi, Mahdieh Shokrollahi Barough, Saeed Khalili, Zahra Hosseini-Farjam, Majid Mossahebi-Mohammadi, Alireza Sheidary, Ardeshir Ghavamzadeh, Ramin Sarrami Forooshani. Novel Delivery of Sorafenib by Natural Killer Cell-Derived Exosomes-Enhanced Apoptosis in Triple-Negative Breast Cancer. Nanomedicine 2023; 18(5): 437 doi: 10.2217/nnm-2022-0237
|
| 9 |
Alfeu Zanotto-Filho, Subapriya Rajamanickam, Eva Loranc, V. Pragathi Masamsetti, Aparna Gorthi, July Carolina Romero, Sonal Tonapi, Rosangela Mayer Gonçalves, Robert L. Reddick, Raymond Benavides, John Kuhn, Yidong Chen, Alexander J.R. Bishop. Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. Cancer Letters 2018; 425: 101 doi: 10.1016/j.canlet.2018.03.037
|
| 10 |
Jian Li, Kathrin Halfter, Mengying Zhang, Christian Saad, Kai Xu, Bernhard Bauer, Yijiang Huang, Lei Shi, Ulrich R. Mansmann. Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: implications for treatment and discovery of potential therapeutic signatures. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-5804-0
|
| 11 |
Yujie Shi, Zongmin Zhao, Kevin Peng, Yongsheng Gao, Debra Wu, Jayoung Kim, Samir Mitragotri. Enhancement of Anticancer Efficacy and Tumor Penetration of Sorafenib by Ionic Liquids. Advanced Healthcare Materials 2021; 10(2) doi: 10.1002/adhm.202001455
|
| 12 |
Debasis Das, Jian Hong. Recent Progress and Development of Small Molecule Kinase Inhibitors for the Treatment of Breast Cancer. Current Enzyme Inhibition 2020; 16(1): 4 doi: 10.2174/1573408016666200228112728
|
| 13 |
Alanoud Altalal, Aliyah Almomen, Musaed Alkholief, Ziyad Binkhathlan, Nourah Z. Alzoman, Aws Alshamsan. Development and validation of a UPLC-MS/MS method for simultaneous detection of doxorubicin and sorafenib in plasma: Application to pharmacokinetic studies in rats. Saudi Pharmaceutical Journal 2023; 31(7): 1317 doi: 10.1016/j.jsps.2023.05.025
|
| 14 |
Rola El Sayed, Lara El Jamal, Sarah El Iskandarani, Jeries Kort, Mahmoud Abdel Salam, Hazem Assi. Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00510
|
| 15 |
Giuseppe Bronte, Daniele Andreis, Sara Bravaccini, Roberta Maltoni, Lorenzo Cecconetto, Alessio Schirone, Alberto Farolfi, Anna Fedeli, Patrizia Serra, Caterina Donati, Dino Amadori, Andrea Rocca. Sorafenib for the treatment of breast cancer. Expert Opinion on Pharmacotherapy 2017; 18(6): 621 doi: 10.1080/14656566.2017.1309024
|
| 16 |
Bruna R. Silva, Rita Rebelo, Juliana M. Rodrigues, Cristina P. R. Xavier, M. Helena Vasconcelos, Maria-João R. P. Queiroz. Synthesis of Novel Methyl 3-(hetero)arylthieno[3,2-b]pyridine-2-carboxylates and Antitumor Activity Evaluation: Studies In Vitro and In Ovo Grafts of Chick Chorioallantoic Membrane (CAM) with a Triple Negative Breast Cancer Cell Line. Molecules 2021; 26(6): 1594 doi: 10.3390/molecules26061594
|
| 17 |
Hua-Li Wang, Xue Ma, Xin-Yuan Guan, Chen Song, Guo-Bo Li, Ya-Mei Yu, Ling-Ling Yang. Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib. Pharmacological Research 2022; 177: 106050 doi: 10.1016/j.phrs.2021.106050
|
| 18 |
Fiona L. Cousins, Dorien F. O, Caroline E. Gargett. Endometrial stem/progenitor cells and their role in the pathogenesis of endometriosis. Best Practice & Research Clinical Obstetrics & Gynaecology 2018; 50: 27 doi: 10.1016/j.bpobgyn.2018.01.011
|
| 19 |
Leilei Gou, Grace Gar-Lee Yue, Pema Tenzin Puno, Clara Bik-San Lau. A review on the relationship of mast cells and macrophages in breast cancer — Can herbs or natural products facilitate their anti-tumor effects?. Pharmacological Research 2021; 164: 105321 doi: 10.1016/j.phrs.2020.105321
|
| 20 |
Hebatullah M. Abou El-Fadl, Naglaa M. Hagag, Reham A. El-Shafei, Mohamed H. Khayri, Gamalat El-Gedawy, Ahmed I. Abd El Maksoud, Doaa D. Mohamed, Dalia D. Mohamed, Ibrahim El Halfawy, Ahmed I. Khoder, Khaled A. Elawdan, Mohamed F. Elshal, Ahmed Salah, Hany Khalil. Effective Targeting of Raf-1 and Its Associated Autophagy by Novel Extracted Peptide for Treating Breast Cancer Cells. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.682596
|
| 21 |
Fatemeh Khojasteh Poor, Mona Keivan, Mohammad Ramazii, Farhoodeh Ghaedrahmati, Amir Anbiyaiee, Samira Panahandeh, Seyed Esmaeil Khoshnam, Maryam Farzaneh. Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer. Breast Disease 2021; 40(2): 51 doi: 10.3233/BD-201063
|
| 22 |
Jin Shang, Shanling Xu, Jiaxing Zhang, Xuting Ran, Lang Bai, Hong Tang. Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis. Oncotarget 2017; 8(65): 109723 doi: 10.18632/oncotarget.21299
|
| 23 |
Jing Zhang, Kun Yu, Xuedong Han, Linlin Zhen, Minmin Liu, Xiwen Zhang, Yi Ren, Jianhua Shi. Paeoniflorin influences breast cancer cell proliferation and invasion via inhibition of the Notch‑1 signaling pathway. Molecular Medicine Reports 2017; doi: 10.3892/mmr.2017.8002
|
| 24 |
Kaiwen Zhou, Mengmeng Zhang, Duanyang Zhai, Zilin Wang, Ting Liu, Yubin Xie, Yawei Shi, Huijuan Shi, Qianjun Chen, Xiaoping Li, Juan Xu, Zhenhai Cai, Yunjian Zhang, Nan Shao, Ying Lin. Genomic and transcriptomic profiling of inflammatory breast cancer reveals distinct molecular characteristics to non-inflammatory breast cancers. Breast Cancer Research and Treatment 2024; 208(2): 441 doi: 10.1007/s10549-024-07437-0
|
| 25 |
Nishtha Chaurawal, Charu Misra, Harshita Abul Barkat, Reena Jatyan, Deepak Chitkara, Md. Abul Barkat, Teenu Sharma, Bhupinder Singh, Kaisar Raza. Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations and pharmacokinetic studies. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-17333-6
|
| 26 |
Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer. Aging 2021; 13(2): 1872 doi: 10.18632/aging.103905
|
| 27 |
Ahmed A. Abdelgalil, Hamad M. Alkahtani, Fahad I. Al-Jenoobi. Profiles of Drug Substances, Excipients, and Related Methodology. Profiles of Drug Substances, Excipients and Related Methodology 2019; 44: 239 doi: 10.1016/bs.podrm.2018.11.003
|
| 28 |
Agnieszka Karbownik, Katarzyna Sobańska, Tomasz Grabowski, Joanna Stanisławiak-Rudowicz, Anna Wolc, Edmund Grześkowiak, Edyta Szałek. In vivo assessment of the drug interaction between sorafenib and paracetamol in rats. Cancer Chemotherapy and Pharmacology 2020; 85(6): 1039 doi: 10.1007/s00280-020-04075-3
|
| 29 |
Taobo Hu, Wei Hou, Enhua Xiao, Mengping Long. Mechanism and effect of stress granule formation in cancer and its potential roles in breast cancer therapy. Genes & Diseases 2022; 9(3): 659 doi: 10.1016/j.gendis.2021.02.005
|
| 30 |
Doaa S. R. Khafaga, Ahmed M. El-Khawaga, Rehab Abd Elfattah Mohammed, Heba K. Abdelhakim. Green synthesis of nano-based drug delivery systems developed for hepatocellular carcinoma treatment: a review. Molecular Biology Reports 2023; 50(12): 10351 doi: 10.1007/s11033-023-08823-5
|
| 31 |
Jia Fu, Wenpan Li, Xiu Xin, Dawei Chen, Haiyang Hu. Transferrin-Modified Nanoliposome Codelivery Strategies for Enhancing the Cancer Therapy. Journal of Pharmaceutical Sciences 2020; 109(8): 2426 doi: 10.1016/j.xphs.2019.11.013
|
| 32 |
Yogita Chhichholiya, Prabhat Suman, Sandeep Singh, Anjana Munshi. The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies. Medical Oncology 2021; 38(8) doi: 10.1007/s12032-021-01547-1
|
| 33 |
Francesca Laneri, Adriana C. E. Graziano, Mimimorena Seggio, Aurore Fraix, Milo Malanga, Szabolcs Béni, Giuseppe Longobardi, Claudia Conte, Fabiana Quaglia, Salvatore Sortino. Enhancing the Anticancer Activity of Sorafenib through Its Combination with a Nitric Oxide Photodelivering β-Cyclodextrin Polymer. Molecules 2022; 27(6): 1918 doi: 10.3390/molecules27061918
|
| 34 |
Bui Thanh Tung, Nguyen Nhu Son, Nguyen Bao Kim, Do Thi Hong Khanh, Phan Hong Minh. In silico screening of alkaloids as potential inhibitors of HER2 protein for breast cancer treatment. Vietnam Journal of Chemistry 2023; 61(3): 308 doi: 10.1002/vjch.202200135
|
| 35 |
Ahmed Elwakeel, Hadeer Soudan, Ahmad Eldoksh, Manal Shalaby, Maha Eldemellawy, Doaa Ghareeb, Myriam Abouseif, Amira Fayad, Mostafa Hassan, Hesham Saeed. Implementation of the Chou-Talalay method for studying the in vitro pharmacodynamic interactions of binary and ternary drug combinations on MDA-MB-231 triple negative breast cancer cells. Synergy 2019; 8: 100047 doi: 10.1016/j.synres.2019.100047
|
| 36 |
Nidhi Gupta, Hitesh Kumar, Sumeet Gupta, Basavarajaiah S. M., Kamal Saini. A Concise Review on Natural Products and Their Derivatives for Breast Cancer Treatment. Chemistry & Biodiversity 2023; 20(8) doi: 10.1002/cbdv.202300688
|
| 37 |
Sreeja Dattachoudhury, Renu Sharma, Atul Kumar, Bithiah Grace Jaganathan. Sorafenib Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells. Oncology 2020; 98(7): 478 doi: 10.1159/000505521
|
| 38 |
Hossam M. S. Nabawi, Ahmed Z. Abdelazem, Waleed M. A. El Rouby, Ahmed A. G. El‐Shahawy. A potent formula against triple‐negative breast cancer—sorafenib‐carbon nanotubes‐folic acid: Targeting, apoptosis triggering, and bioavailability enhancing. Biotechnology and Applied Biochemistry 2024; doi: 10.1002/bab.2649
|
| 39 |
Joanna Wawszczyk, Radosław Wolan, Sławomir Smolik, Małgorzata Kapral. In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells. Saudi Pharmaceutical Journal 2023; 31(7): 1306 doi: 10.1016/j.jsps.2023.05.020
|
| 40 |
Zeynep Oruç, Muhammet Ali Kaplan, Çağatay Arslan. An update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients. Expert Opinion on Pharmacotherapy 2018; 19(12): 1305 doi: 10.1080/14656566.2018.1504922
|
| 41 |
Teresa Faranda, Ilaria Grossi, Michele Manganelli, Eleonora Marchina, Gianluca Baiocchi, Nazario Portolani, Marialuisa Crosatti, Giuseppina De Petro, Alessandro Salvi. Differential expression profiling of long non-coding RNA GAS5 and miR-126-3p in human cancer cells in response to sorafenib. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-45604-2
|